Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today?

TG Therapeutics Inc (NASDAQ: TGTX) reported Q3 FY23 Briumvi sales of $25.1 million compared to $16 million in Q2 FY23 in the U.S., with total net product revenue of approximately


Posted

in

by

Tags: